Tomas Heyman Net Worth

The estimated Net Worth of Tomas J. Heyman is at least 666 千$ dollars as of 16 June 2023. Mr. Heyman owns over 26,000 units of Akero Therapeutics Inc stock worth over 666,120$ and over the last 4 years he sold AKRO stock worth over 0$. In addition, he makes 0$ as Independent Director at Akero Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Heyman AKRO stock SEC Form 4 insiders trading

Tomas has made over 1 trades of the Akero Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 26,000 units of AKRO stock worth 651,040$ on 16 June 2023.

The largest trade he's ever made was exercising 26,000 units of Akero Therapeutics Inc stock on 16 June 2023 worth over 651,040$. On average, Tomas trades about 2,000 units every 0 days since 2020. As of 16 June 2023 he still owns at least 26,000 units of Akero Therapeutics Inc stock.

You can see the complete history of Mr. Heyman stock trades at the bottom of the page.

Tomas Heyman biography

Tomas J. Heyman serves as Independent Director of the Company. Mr. Heyman most recently was the President of Johnson & Johnson Development Corporation, the corporate venture capital group of Johnson & Johnson, from April 2015 until September 2019. He also served as the Global Head of Business Development, Pharmaceuticals Group of Janssen Global Services, LLC from March 1992 to March 2015, and served as the CEO of Janssen Pharmaceutica NV in Belgium from November 2008 to November 2016. He currently serves on the board of directors of IMEC VZW in Belgium. Mr. Heyman received his Master of Law degree from Katholieke Universiteit Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in Business Management at the University of Antwerp in Belgium.

What's Tomas Heyman's mailing address?

Tomas's mailing address filed with the SEC is 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over 146,260,704$ worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth 104,250,550$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Trust Blue Horizon Enterpri...、G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,642,344$. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth 133,600$.

What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Complete history of Mr. Heyman stock trades at Exelixis Inc、OptiNose Inc、Akero Therapeutics Inc

Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Cheng,
  President, Chief Executive Officer, Director
• William White,
  Chief Financial Officer, Executive Vice President and Head of Corporate Development
• Timothy Rolph,
  Co-Founder, Chief Scientific Officer
• Jonathan Young,
  Co-Founder, Chief Operating Officer, Executive Vice President
• Dr. Andrew Cheng,
  Pres, CEO & Director
• Dr. Timothy Rolph,
  Co-Founder & Chief Scientific Officer
• Dr. Jonathan M. Young,
  Co-Founder, Exec. VP, COO & Sec.
• William R. White J.D.,
  Exec. VP, CFO, Treasurer & Head of Corp. Devel.
• Mark Iwicki,
  Independent Non-Executive Chairman of the Board
• Kevin Bitterman,
  Non-Executive Independent Director
• Seth Harrison,
  Non-Executive Independent Director
• Graham Walmsley,
  Non-Executive Independent Director
• Kitty Yale,
  Chief Development Officer
• Jane Henderson,
  Non-Executive Independent Director
• Tomas Heyman,
  Independent Director
• Kitty Yale,
  Exec. VP & Chief Devel. Officer
• John J. Schembri,
  VP of Fin. & Controller
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Trust Blue Horizon Enterpri...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Group, Llc Green Jeremy Red...,
  
• Global Strategic Fund Ii L....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Aaron Royston,
  Director
• Venture Capital Vi, L.P. Ve...,
  10% owner
• Life Science Ventures, L.P....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Venture Opportunity Fund I,...,
  10% owner
• Chou Judy,
  
• Catriona Yale,
  Chief Development Officer
• Yuan Xu,
  
• Scott A. Gangloff,
  Chief Technology Officer
• Patrick Lamy,
  Senior VP, Commercial Strategy